Exvastat Ltd.   Report issue

For profit Phase 2
Founded: Cambridge United Kingdom (2016)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2017
NCT03328117
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Exvastat Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

imatinib (gleevec) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 1)

Lung Injury (Phase 1)

Respiratory Distress Syndrome (Phase 1)

Wounds and Injuries (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1